

ENDURING MATERIAL LEARNER NOTIFICATION

THC - A multidisciplinary review of Key #ASCO20 GI Updates

Date of CE Release: June 18, 2020

Date of CE Expiration: June 18, 2023

Location: Online

Acknowledgement of Financial Commercial Support

No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Physicians / Nurses / Pharmacists



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health Conferencing. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this enduring activity for a maximum of 1.75 *AMA PRA Category 1 Credits*[™] for physicians and 1.75 contact hours for nurses and 1.75 of knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.

NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.

Objectives - After attending this program you should be able to:

1. Review Key Studies from the 2020 ASCO Annual Meeting including OPRA, PRODIGE, and RAPIDO
2. Discuss the multidisciplinary approach in total neoadjuvant therapy (TNT) in rectal cancer as a viable treatment strategy in patients with rectal cancers.
3. Review Abstract 4108 on the Tumor Informed Assessment of molecular residual disease (MRD) rates and quantification of ctDNA in patients with colon cancers and Discuss multidisciplinary application of ctDNA and MRD in clinical practice as a diagnostic and screening tool.

Disclosures of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First	Last	Commercial Interest
Julio	Garcia Aguilar	NA

First	Last	Commercial Interest
Thomas	George	NA
Manju	George	Paltown Development Foundation:Employee
Axel	Grothey	Bayer, Roche/ Genentech, Daiichi, Array, Eli Lilly, Merck, Boston Biomedicals:Research Grant Overall Principal Investigator,Bayer, Roche/ Genentech, Daiichi, Array, Eli Lilly, Merck, Boston Biomedicals, Regeneron:Consultant
Nina	Sanford	NA
Joshua	Smith	Guardant Health, Inc.:Scientific/Medical Advisory Board Member
Noam	Vanderwalde	NA

How to Get Your Certificate:

1. CME Link: <https://workshop-evaluator.herokuapp.com/evaluation/7292>
2. Evaluate the meeting.
3. Print all pages of your certificate for your records.

Questions? Email Certificate@AmedcoEmail.com